News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eisai Company, Ltd. (ESALY.PK) In-licenses Anti-hepatitis B Agent Clevudine From Bukwang Pharm. Ind. Co., Ltd. (South Korea)


10/19/2005 5:12:13 PM

Eisai Co., Ltd. (TSE: 4523) announced today that the Company has in-licensed an anti-hepatitis B agent (generic name: clevudine) from Bukwang Pharm (Headquarters, Seoul, South Korea, President: Sung-Koo Lee).

Read at JCN Newswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES